5.64
+0.205(+3.78%)
Currency In USD
| Previous Close | 5.43 |
| Open | 5.47 |
| Day High | 5.71 |
| Day Low | 5.47 |
| 52-Week High | 896 |
| 52-Week Low | 4.27 |
| Volume | 50,512 |
| Average Volume | 1.2M |
| Market Cap | 6.79M |
| PE | -0.02 |
| EPS | -363.01 |
| Moving Average 50 Days | 7.67 |
| Moving Average 200 Days | 43.65 |
| Change | 0.21 |
If you invested $1000 in CERo Therapeutics Holdings, Inc. (CERO) since IPO date, it would be worth $0.28 as of September 16, 2025 at a share price of $5.635. Whereas If you bought $1000 worth of CERo Therapeutics Holdings, Inc. (CERO) shares 3 years ago, it would be worth $0.28 as of September 16, 2025 at a share price of $5.635.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
GlobeNewswire Inc.
Sep 09, 2025 12:15 PM GMT
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology SOUTH SAN FRANSCISCO, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- CERo Therapeu
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia
GlobeNewswire Inc.
Sep 08, 2025 12:45 PM GMT
Study investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13th annual conference highlighting original study protocol SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.,
CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)
GlobeNewswire Inc.
Sep 05, 2025 12:00 PM GMT
Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company’s lead cancer immunotherapy program SOUTH SAN FRANSCISCO, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- CERo The